User profiles for R. ARANDA

Ramon Aranda

CONACYT / CIMAT
Verified email at cimat.mx
Cited by 606

[HTML][HTML] Natural language processing applied to tourism research: A systematic review and future research directions

MÁ Álvarez-Carmona, R Aranda… - Journal of King Saud …, 2022 - Elsevier
The social networks and the rapid development of new technologies have led to considerable
changes in the tourism industry. Artificial intelligence, in particular natural language …

[HTML][HTML] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition

…, K Natarajan, I Nuamah, T Li, R Aranda… - … England Journal of …, 2005 - Mass Medical Soc
Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda… - Cancer discovery, 2020 - AACR
The discovery of MRTX849 provides a long-awaited opportunity to selectively target KRAS
G12C in patients. The in-depth characterization of MRTX849 activity, elucidation of response …

Review and future prospects for DNA barcoding methods in forensic palynology

KL Bell, KS Burgess, KC Okamoto, R Aranda… - Forensic Science …, 2016 - Elsevier
Pollen can be a critical forensic marker in cases where determining geographic origin is
important, including investigative leads, missing persons cases, and intelligence applications. …

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with …

…, S Nayiager, C Saldate, T Li, R Aranda… - Annals of the …, 2008 - ard.bmj.com
Objectives: This double-blind trial evaluated the efficacy and safety of abatacept or infliximab
vs placebo. The primary objective of this study was to evaluate the mean change from …

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase IIb, double‐blind, randomized, placebo …

…, JC Becker, T Li, IF Nuamah, R Aranda… - … : Official Journal of …, 2005 - Wiley Online Library
Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying …

…, B Combe, A Covucci, R Aranda… - Arthritis & …, 2006 - Wiley Online Library
Objective To assess the safety of abatacept, a selective costimulation modulator, in patients
with active rheumatoid arthritis (RA) who had been receiving ≥1 traditional nonbiologic and/…

[HTML][HTML] Ozanimod induction and maintenance treatment for ulcerative colitis

…, M Cravets, PA Frohna, R Aranda… - … England Journal of …, 2016 - Mass Medical Soc
Background Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate
receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially …

Mice with combined disruption of Gpx1 andGpx2 genes have colitis

RS Esworthy, R Aranda, MG Martín… - American Journal …, 2001 - journals.physiology.org
Glutathione peroxidase (GPX)-1 and gastrointestinal (GI) epithelium-specific GPX (GPX-GI),
encoded byGpx1 and Gpx2, provide most GPX activity in GI epithelium. Although …

Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients.

R Aranda, BC Sydora, PL McAllister… - … (Baltimore, Md.: 1950 …, 1997 - journals.aai.org
Transfer of specific T lymphocyte subsets isolated from the spleens of healthy donor mice
into immunodeficient SCID mice leads to chronic intestinal inflammation with characteristics …